Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries.

about

Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries.

Item

http://www.wikidata.org/entity/Q39173721

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Home treatment of haemarthrosi ...... nce from developing countries.

@en

Home treatment of haemarthrosi ...... nce from developing countries.

@nl

type

Item

label

Home treatment of haemarthrosi ...... nce from developing countries.

@en

Home treatment of haemarthrosi ...... nce from developing countries.

@nl

prefLabel

Home treatment of haemarthrosi ...... nce from developing countries.

@en

Home treatment of haemarthrosi ...... nce from developing countries.

@nl

P1476

Home treatment of haemarthrosi ...... nce from developing countries.

@en

P2093

Abdulkareem Almomen

http://www.w3.org/2001/XMLSchema#string

Azzam Alzoebie

http://www.w3.org/2001/XMLSchema#string

Fati Hamzy

http://www.w3.org/2001/XMLSchema#string

Fatiha Grifi

http://www.w3.org/2001/XMLSchema#string

Hadj Touhami

http://www.w3.org/2001/XMLSchema#string

Hossam Ali Saad

http://www.w3.org/2001/XMLSchema#string

Meriem Bensadok

http://www.w3.org/2001/XMLSchema#string

Naima Mesli

http://www.w3.org/2001/XMLSchema#string

Nemra Gaid Mehalhal

http://www.w3.org/2001/XMLSchema#string

Nouredine Sidi Mansour

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic.

Definitions for haemophilia prophylaxis and its outcomes: the Canadian consensus study.

Modern management of haemophilic arthropathy.

Optimizing outcomes for patients with severe haemophilia A.

Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008).

Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry.

When should prophylactic treatment in patients with haemophilia A and B start?--The German experience.

Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention.

Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).

Health status and health-related quality of life of children with haemophilia from six West European countries.

P304

145-151

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MBC.0000000000000564

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27100303

http://www.w3.org/2001/XMLSchema#string

P921

hemophilia

hemophilia A

P932

5312720

http://www.w3.org/2001/XMLSchema#string